Background & Aims: Toll-like receptor 4 (TLR4) signaling is activated through 2 adaptor proteins: MyD88 and TIR-domain containing adaptor-inducing interferon-β (TRIF). TLR4 and MyD88 are crucial in nonalcoholic steatohepatitis (NASH) and fibrosis. However, the role of TRIF in TLR4-mediated NASH and fibrosis has been elusive. This study investigated the differential roles of TRIF in hepatic steatosis and inflammation/fibrosis. Methods: A choline-deficient amino acid defined (CDAA) diet was used for the mouse NASH model. On this diet, the mice develop hepatic steatosis, inflammation, and fibrosis. TLR4 wild-type and TLR4-/- bone marrow chimeric mice and TRIF-/- mice were fed CDAA or a control diet for 22 weeks. Hepatic steatosis, inflamm...
BACKGROUND/AIMS: The molecular mechanisms leading to Non-Alcoholic Steatohepatitis (NASH) are not fu...
The development of hepatocellular carcinoma (HCC) is a common consequence of advanced liver fibrosis...
Nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease in the US, partly due t...
Background & aimsToll-like receptor 4 (TLR4) signaling is activated through 2 adaptor proteins: ...
Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of diseases that ranges in severity fro...
Toll-like receptor 4 (TLR4), and its co-receptor, Myeloid Differentiation Factor 2 (MD-2), are key i...
Background: Non-alcoholic fatty liver disease is an obesity-related chronic liver disorder ranging f...
BACKGROUND and AIMS: Inflammation promotes the progression of non-alcoholic steatohepatitis (NASH). ...
Abstract Background Previously we reported that mice deficient in toll-like receptor 4 (TLR-4) signa...
Background and aims: TLR9 deletion protects against steatohepatitis due to choline-amino acid deplet...
Category: Integrated Physiology - Liver: abstract no. 1655-PRESULTS: Nonalcoholic steatohepatitis (N...
Toll-like receptors (TLR) recognize pathogen-derived molecules and induce downstream activation of i...
Hepatic injury is associated with a defective intestinal barrier and increased hepatic exposure to b...
Conference Theme: A Decade of Positive AgingInflammation is commonly observed in many chronic diseas...
Regulating dietary fat absorption may impact progression of nonalcoholic fatty liver disease (NAFLD)...
BACKGROUND/AIMS: The molecular mechanisms leading to Non-Alcoholic Steatohepatitis (NASH) are not fu...
The development of hepatocellular carcinoma (HCC) is a common consequence of advanced liver fibrosis...
Nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease in the US, partly due t...
Background & aimsToll-like receptor 4 (TLR4) signaling is activated through 2 adaptor proteins: ...
Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of diseases that ranges in severity fro...
Toll-like receptor 4 (TLR4), and its co-receptor, Myeloid Differentiation Factor 2 (MD-2), are key i...
Background: Non-alcoholic fatty liver disease is an obesity-related chronic liver disorder ranging f...
BACKGROUND and AIMS: Inflammation promotes the progression of non-alcoholic steatohepatitis (NASH). ...
Abstract Background Previously we reported that mice deficient in toll-like receptor 4 (TLR-4) signa...
Background and aims: TLR9 deletion protects against steatohepatitis due to choline-amino acid deplet...
Category: Integrated Physiology - Liver: abstract no. 1655-PRESULTS: Nonalcoholic steatohepatitis (N...
Toll-like receptors (TLR) recognize pathogen-derived molecules and induce downstream activation of i...
Hepatic injury is associated with a defective intestinal barrier and increased hepatic exposure to b...
Conference Theme: A Decade of Positive AgingInflammation is commonly observed in many chronic diseas...
Regulating dietary fat absorption may impact progression of nonalcoholic fatty liver disease (NAFLD)...
BACKGROUND/AIMS: The molecular mechanisms leading to Non-Alcoholic Steatohepatitis (NASH) are not fu...
The development of hepatocellular carcinoma (HCC) is a common consequence of advanced liver fibrosis...
Nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease in the US, partly due t...